10 March 2025
EMA/PRAC/54646/2025
Human Medicines Division

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda for the meeting on 10-13 March 2025

Chair: Ulla Wändel Liminga – Vice-Chair: Liana Martirosyan

10 March 2025, 13:00 – 19:30, via teleconference

11 March 2025, 08:30 – 19:30, via teleconference

12 March 2025, 08:30 – 19:30, via teleconference

13 March 2025, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)

27 March 2025, 09:00 – 12:00, via teleconference

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006 Rev.1).

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 10-13 March 2025. See March 2025 PRAC minutes (to be published post April 2025 PRAC meeting).

1.2. Agenda of the meeting on 10-13 March 2025

Action: For adoption

1.3. Minutes of the previous meeting on 10-13 February 2025

Action: For adoption

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

None

3.2. Ongoing procedures

None

3.3. Procedures for finalisation

None

3.4. Re-examination procedures[1]

None

3.5. Others

None

4. Signals assessment and prioritisation[2]

4.1. New signals detected from EU spontaneous reporting systems and/or other sources

4.1.1. Binimetinib – MEKTOVI (CAP); cobimetinib – COTELLIC (CAP); dabrafenib – TAFINLAR (CAP), FINLEE (CAP); encorafenib – BRAFTOVI (CAP); trametinib – MEKINIST (CAP), SPEXOTRAS (CAP); vemurafenib – ZELBORAF (CAP)

Applicants: Novartis Europharm Limited (Finlee, Mekinist, Spexotras, Tafinlar), Pierre Fabre Medicament (Braftovi, Mektovi), Roche Registration GmbH (Cotellic, Zelboraf)

PRAC Rapporteur: To be appointed

Scope: Signal of tattoo associated skin reaction

Action: For adoption of PRAC recommendation

EPITT 20160 – New signal

Lead Member State(s): LT, NL, NO, PT, SE

4.1.2. Leflunomide – ARAVA (CAP), LEFLUNOMIDE MEDAC (CAP), LEFLUNOMIDE RATIOPHARM (CAP), LEFLUNOMIDE ZENTIVA (CAP); NAP

Applicant(s): Medac Gesellschaft fur klinische (Leflunomide medac), Ratiopharm GmbH (Leflunomide ratiopharm), Sanofi-Aventis Deutschland GmbH (Arava), Zentiva, k.s. (Leflunomide Zentiva), various

PRAC Rapporteur: To be appointed

Scope: Signal of pulmonary nodule

Action: For adoption of PRAC recommendation

EPITT 20155 – New signal

[1] Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
[2] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required

Lead Member State(s): NL

4.2. Signals follow-up and prioritisation

4.2.1. Canagliflozin - INVOKANA (CAP) - EMEA/H/C/002649/SDA/020; canagliflozin, metformin - VOKANAMET (CAP) - EMEA/H/C/002656/SDA/017; dapagliflozin - EDISTRIDE (CAP) - EMEA/H/C/004161/SDA/017, FORXIGA (CAP) - EMEA/H/C/002322/SDA/030, DAPAGLIFLOZIN VIATRIS, NAP; dapagliflozin, metformin - EBYMECT (CAP) - EMEA/H/C/004162/SDA/015, XIGDUO (CAP) - EMEA/H/C/002672/SDA/018, NAP; empagliflozin - JARDIANCE (CAP) - EMEA/H/C/002677/SDA/019; empagliflozin, linagliptin - GLYXAMBI (CAP) - EMEA/H/C/003833/SDA/010; empagliflozin, metformin - SYNJARDY (CAP) - EMEA/H/C/003770/SDA/012; ertugliflozin - STEGLATRO (CAP) - EMEA/H/C/004315/SDA/008; ertugliflozin, metformin hydrochloride - SEGLUROMET (CAP) - EMEA/H/C/004314/SDA/006; ertugliflozin, sitagliptin - STEGLUJAN (CAP) - EMEA/H/C/004313/SDA/007; saxagliptin, dapagliflozin - QTERN (CAP) - EMEA/H/C/004057/SDA/010

Applicants: AstraZeneca AB (Ebymect, Edistride, Forxiga, Qtern, Xigduo), Boehringer Ingelheim International GmbH (Glyxambi, Jardiance, Synjardy), Janssen-Cilag International N.V. (Invocana, Vokanamet), Merck Sharp & Dohme B.V. (Segluromet, Steglatro, Steglujan), Viatris Limited (Dapagliflozin Viatris), various

PRAC Rapporteur: Mari Thorn

Scope: Signal of sarcopenia

Action: For adoption of PRAC recommendation

EPITT 20111 – Follow-up to September 2024

4.2.2. Ixekizumab - TALTZ (CAP) - EMEA/H/C/003943/SDA/006

Applicant: Eli Lilly and Co (Ireland) Limited

PRAC Rapporteur: Gabriele Maurer

Scope: Signal of demyelinating disorders

Action: For adoption of PRAC recommendation

EPITT 20124 – Follow-up to November 2024

4.2.3. Tegafur, gimeracil, oteracil - TEYSUNO (CAP) - EMEA/H/C/001242/SDA/015

Applicant: Nordic Group B.V.

PRAC Rapporteur: Bianca Mulder

Scope: Signal of hyperammonaemia

Action: For adoption of PRAC recommendation

EPITT 20115 – Follow-up to November 2024

4.3. Variation procedure(s) resulting from signal evaluation

None

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Aflibercept (CAP MAA) - EMEA/H/C/006745

Scope: Treatment of age-related macular degeneration (AMD) and visual impairment

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Aflibercept (CAP MAA) - EMEA/H/C/006192

Scope (pre D-180 phase): Treatment of age-related macular degeneration (AMD) and visual impairment

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Autologous cartilage-derived articular chondrocytes, in-vitro expanded (CAP MAA) - EMEA/H/C/004594

Scope (pre D-180 phase): Repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.1.4. Denosumab (CAP MAA) - EMEA/H/C/006269

Scope (pre D-180 phase): Prevention of skeletal related events in adults with advanced malignancies involving bone

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.5. Denosumab (CAP MAA) - EMEA/H/C/006268

Scope (pre D-180 phase): Treatment of osteoporosis and bone loss

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.6. Denosumab (CAP MAA) - EMEA/H/C/006526

Scope (pre D-180 phase): Treatment of osteoporosis and bone loss

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.7. Denosumab (CAP MAA) - EMEA/H/C/006534

Scope (pre D-180 phase): Prevention of skeletal related events in adults with advanced malignancies involving bone

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. Dorocubicel, allogeneic umbilical cord-derived CD34- cells, non-expanded (CAP MAA) - EMEA/H/C/005772, PRIME, Orphan

Applicant: Cordex Biologics International Limited, ATMP

Scope (pre D-180 phase): Treatment of adult patients with haematological malignancies

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.1.9. Emtricitabine, tenofovir alafenamide (CAP MAA) - EMEA/H/C/006469

Scope (pre D-180 phase): For the treatment of human immunodeficiency virus type 1 (HIV-1)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.10. Obecabtagene autoleucel (CAP MAA) - EMEA/H/C/005907, PRIME, Orphan

Applicant: Autolus GmbH, ATMP

Scope (pre D-180 phase): Treatment of patients with relapsed or refractory B cell precursor acute lymphoblastic leukaemia (ALL)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.1.11. Resmetirom (CAP MAA) - EMEA/H/C/006220

Scope (pre D-180 phase): For the treatment of adults with non-alcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.12. Tegomil fumarate (CAP MAA) - EMEA/H/C/006427

Scope (pre D-180 phase): Treatment of multiple sclerosis

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Avanafil – SPEDRA (CAP) - EMA/VR/0000243987

Applicant(s): Menarini International Operations Luxembourg S.A.

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Submission of an updated RMP version 6.0 in order to align with the GVP Module V on Risk Management Systems (EMA/838713/2011 Rev2*, 28 March 2017) and to update the list of safety concerns, according to the outcome of the latest two PSUSA procedures (EMEA/H/C/PSUSA/00010066/202006 and EMEA/H/C/PSUSA/00010066/202306)

Action: For adoption of PRAC Assessment Report

5.2.2. Clopidogrel - ISCOVER (CAP) - EMEA/H/C/000175/WS2808/0158; Clopidogrel - PLAVIX (CAP) - EMEA/H/C/000174/WS2808/0160

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Carla Torre

Scope: C.I.11.z (IB) - To provide a new RMP version to update the FUQ in Annex 4.

Furthermore, the Marketing Authorisation Holder has taken the opportunity to update Part I Table 5 Product overview following approval of EMEA/H/C/WS/2150

Action: For adoption of PRAC Assessment Report

5.2.3. Umeclidinium, vilanterol - ANORO ELLIPTA (CAP) - EMEA/H/C/002751/WS2815/0049; Umeclidinium, vilanterol - LAVENTAIR ELLIPTA (CAP) - EMEA/H/C/003754/WS2815/0052

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Amelia Cupelli

Scope: Submission of an updated RMP version 10.0 for Anoro Ellipta and Laventair Ellipta Inhalation powder, pre-dispensed [55µg/ 22µg] following completion of Category 1 PASS 201038 in order to remove the safety concerns accordingly

Action: For adoption of PRAC Assessment Report

5.2.4. Umeclidinium bromide - INCRUSE ELLIPTA (CAP) - EMEA/H/C/002809/WS2816/0043; Umeclidinium - ROLUFTA ELLIPTA (CAP) - EMEA/H/C/004654/WS2816/0027

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Amelia Cupelli

Scope: Submission of an updated RMP version 8.0 for Incruse Ellipta and Rolufta Ellipta in order to reflect the completion of the category 1 PASS study 201038 and remove the safety concerns accordingly.

Action: For adoption of PRAC Assessment Report

5.2.5. Zoledronic Acid – ZOLEDRONIC ACID ACCORD (CAP); NAP - EMA/VR/0000226953

Applicant(s): Accord Healthcare S.L.U., various

PRAC Rapporteur: Karin Erneholm

Scope: To align the RMP for Zoledronic Acid Accord with the RMP of the reference product. In addition for the nationally authorised products Zoledronic Acid Accord 4 mg/5 ml, 4 mg/100 ml concentrate for solution for infusion (product reference PT/H/0742/001/DC) the RMP is being merged with the RMP of the centrally authorised product

Action: For adoption of PRAC Assessment Report

5.3. Medicines in the post-authorisation phase – CHMP-led procedures

5.3.1. Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/II/0025

Applicant: AstraZeneca AB

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Extension of indication to include CALQUENCE in combination with bendamustine and rituximab (BR) as treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL) based on interim results from study ACE-LY-308 (ECHO, D8220C00004); this is a Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6, succession 1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. As part of the application the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. Adagrasib - KRAZATI (CAP) - EMEA/H/C/006013/II/0010/G

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Kimmo Jaakkola

Scope: A grouped application consisting of:

C.I.4: Update of section 5.1 of the SmPC based on final results from study 849-012 (KRYSTAL-12) listed as a specific obligation in the Annex II. This is a Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to update Annex IIE of the PI.

C.I.4: Update of section 4.8 of the SmPC in order to update safety information based on an integrated analysis of data from interventional studies 849-012 (KRYSTAL-12), 849-007 (KRYSTAL-7) and 849-001 (KRYSTAL-1)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.3. Adalimumab - IDACIO (CAP) - EMEA/H/C/004475/II/0024/G

Applicant: Fresenius Kabi Deutschland GmbH

PRAC Rapporteur: Karin Bolin

Scope: Grouped quality variations

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Afamelanotide - SCENESSE (CAP) - EMEA/H/C/002548/II/0053

Applicant: Clinuvel Europe Limited

PRAC Rapporteur: Martin Huber

Scope: Submission of an updated RMP version 9.12 to include changes made to the pharmacokinetic study CUV052 including the inclusion of adolescent patients in the protocol. CUV052 is an interventional study to evaluate the pharmacokinetics of afamelanotide in patients with Erythropoietic Protoporphyria (EPP)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Asciminib - SCEMBLIX (CAP) - EMEA/H/C/005605/II/0017, Orphan

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Eva Jirsová

Scope: Submission of a comprehensive final analysis of the data from study CABL001X2101, listed as a category 3 study in the RMP. This is a phase I, multicenter, open-label study of oral asciminib in patients with chronic myelogenous leukemia or Philadelphia Chromosome-positive acute lymphoblastic leukemia. The RMP version 2.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.6. Avelumab - BAVENCIO (CAP) - EMEA/H/C/004338/II/0051

Applicant: Merck Europe B.V.

PRAC Rapporteur: Karin Erneholm

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to add "neutropenia" to the list of adverse drug reactions (ADRs) with frequency "not known" based on post marketing data and literature. The Package Leaflet is updated accordingly. The RMP version 8.2 has also been submitted. In addition, the MAH took the opportunity to update the PI in accordance with the latest EMA excipients guideline

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.7. Bosutinib - BOSULIF (CAP) - EMEA/H/C/002373/X/0058/G

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Martin Huber

Scope: Extension application to introduce a new pharmaceutical form (hard capsules) associated with two new strengths (50 mg and 100 mg) grouped with an extension of indication (C.I.6.a) to include treatment of paediatric patients greater than or equal to 1 year of age with newly-diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) for BOSULIF, based on interim results from study ITCC-054/AAML1921 (BCHILD); this is a phase 1/2, multicenter, international, single-arm, open-label study of bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ chronic myeloid leukemia. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 7.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.8. Cabozantinib - CABOMETYX (CAP) - EMEA/H/C/004163/II/0040

Applicant: Ipsen Pharma

PRAC Rapporteur: Bianca Mulder

Scope: Extension of indication to include the treatment of adult patients with progressive extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours after prior systemic therapy for CABOMETYX based on final results from study CABINET (A021602). This is a multicenter, two-arm, randomised, double-blind, placebo-controlled phase 3 study investigating cabozantinib versus placebo in patients with advanced Neuroendocrine Tumors (NET). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.9. Canagliflozin - INVOKANA (CAP) - EMEA/H/C/002649/II/0069

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Martin Huber

Scope: Extension of indication to include treatment of paediatric patients with type 2 diabetes mellitus (T2DM) aged 10 years old and older for INVOKANA, based on final results from study JNJ-28431754DIA3018 as well as study JNJ-28431754DIA1055. Study JNJ-28431754DIA3018 is a double-blind, placebo-controlled, 2-arm, parallel-group, multicenter Phase 3 study in participants with T2DM >10 and <18 years of age who had inadequate glycemic control (ie, HbA1c of >6.5% to <11.0%). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor changes to the PI and update the list of local representatives in the Package Leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. Ciltacabtagene autoleucel - CARVYKTI (CAP) - EMEA/H/C/005095/II/0036, Orphan

Applicant: Janssen-Cilag International NV, ATMP

PRAC Rapporteur: Jo Robays

Scope: Update of sections 4.8, and 5.1 of the SmPC in order to update the list of adverse drug reactions (ADRs), and update clinical efficacy and safety information based on second interim analysis from study 68284528MMY3002 (CARTITUDE-4); this is a phase 3 randomized study comparing ciltacabtagene autoleucel, a chimeric antigen receptor T cell (CAR-T) therapy directed against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in subjects with relapsed and lenalidomide-refractory multiple myeloma; The RMP version 5.3 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.11. Dalbavancin - XYDALBA (CAP) - EMEA/H/C/002840/II/0050

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Rugile Pilviniene

Scope: Extension of indication to include the treatment of acute bacterial skin and skin structure infections (ABSSSI) in paediatric patients from birth, including paediatric patients aged less than 3 months with suspected or confirmed sepsis associated with skin and subcutaneous tissue infections for Xydalba, based on final results from study DUR001-306, together with data from three Phase 1 PK studies (A8841004, DUR001-106, and DUR001-107 (DAL-PK-02); DUR001-306 was a Phase 3, multicenter, open-label, randomized, comparator controlled trial evaluating the safety and efficacy of a single dose of IV dalbavancin and a 2-dose regimen of once weekly IV dalbavancin (for a total of 14 days of coverage) for the treatment of ABSSSI known or suspected to be due to susceptible Gram-positive organisms in children. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI and to update the list of local representatives in the Package Leaflet in line with the latest QRD template version 10.4

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. Elranatamab - ELREXFIO (CAP) - EMEA/H/C/005908/II/0005

Applicant: Pfizer Europe Ma EEIG

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Update of section 4.2 of the SmPC to add every four-week dosing schedule after at least 24 weeks of every two-week dosing and to update the recommendations for restarting therapy following dose delay, and update of sections 4.8, 5.1 and 5.2 of the SmPC with long-term efficacy, safety, and clinical pharmacology results (≥2 years of follow-up after the last participant initial dose), based on the final study report of Study C1071003; a Phase 2, open-label, multicentre, non-randomised study of elranatamab monotherapy in participants with MM who are refractory to at least one PI, one IMiD, and one anti-CD38 Ab. The Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the list of local representatives in

the Package Leaflet. Further, the provision of the final study report addresses SOB 001, and Annex II has been updated accordingly. A revised RMP version 1.2 was provided as part of the application

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.13. Entrectinib - ROZLYTREK (CAP) - EMEA/H/C/004936/II/0025

Applicant: Roche Registration GmbH

PRAC Rapporteur: Bianca Mulder

Scope: Submission of the final integrated analysis report for bone biomarkers based on GO40782 [STARTRK-2], CO40778 [STARTRK-NG], and BO41932 [TAPISTRY] studies (PAESs). The RMP version 6 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. Enzalutamide - ENZALUTAMIDE VIATRIS (CAP) - EMEA/H/C/006299/X/0003

Applicant: Viatris Limited

PRAC Rapporteur: Maria del Pilar Rayon

Scope: Extension application to add a new strength of 160 mg for solution for film-coated tablets.
The RMP (version 1.0) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.15. Ganaxolone - ZTALMY (CAP) - EMEA/H/C/005825/II/0015/G, Orphan

Applicant: Marinus Pharmaceuticals Emerald Limited

PRAC Rapporteur: Adam Przybylkowski

Scope: A grouped application consisting of five Type II variations, as follows:

C.I.13: Submission of the final report from non-clinical study 1022-9241 listed as a category 3 study in the RMP. This is a 26-Week Toxicity Study of Ganaxolone Metabolite, M2, by Oral Gavage in the Sprague-Dawley rat with a 2-Week Recovery Period. The RMP version 3 has also been submitted.

C.I.13: Submission of the final report from non-clinical study 20447815 listed as a category 3 study in the RMP. This is a An Oral (Gavage) Study of the Effects of M2 (Ganaxolone Metabolite) Administration on Embryo/Fetal Development in CD (Sprague Dawley) IGS Rat. The RMP version 3 has also been submitted.

C.I.13: Submission of the final report from Weight of Evidence (WoE) assessment to evaluate the need for a 2-year carcinogenicity study in rats with GNX, listed as a category 3 study in the RMP.

C.I.13: Submission of the final report from WoE assessment to evaluate the need for a 2-year carcinogenicity study in rats with M2, listed as a category 3 study in the RMP.

C.I.13: Submission of the final report from WoE assessment to evaluate the need for a juvenile toxicity study with M2, listed as a category 3 study in the RMP

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.16. Guselkumab - TREMFYA (CAP) - EMEA/H/C/004271/II/0044

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Extension of indication for TREMFYA to include treatment of adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment, based on results from GALAXI Phase 2/3 program and the GRAVITI Phase 3 study. GALAXI is a Phase 2/3, randomized, double-blind, placebo- and active-controlled, parallel-group, multicenter protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active CD who have demonstrated an inadequate response or failure to tolerate previous conventional or biologic therapy. GRAVITI is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of guselkumab SC induction therapy in participants with moderately to severely active CD.
As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2, and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.1 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.17. Herpes zoster vaccine (recombinant, adjuvanted) - SHINGRIX (CAP) - EMEA/H/C/004336/II/0076

Applicant: GlaxoSmithkline Biologicals SA

PRAC Rapporteur: Sonja Hrabcik

Scope: Update of sections 4.8 and 5.1 of the SmPC to include the final results of study ZOSTER-049, listed as a category 3 study in the RMP. This is a Phase 3b, open label, multi-country, long-term follow-up study that assessed the prophylactic efficacy, safety, and immunogenicity persistence of Shingrix in adults ≥50 years of age at the time of primary vaccination in studies ZOSTER 006 and ZOSTER-022. The study also assessed 1 or 2 additional doses of Shingrix on a 0 or 0, 2-month schedule in two subgroups of older adults. The updated RMP version 8.0 is also included. In addition, the MAH took the opportunity to implement editorial changes to the SmPC, Labelling and Package Leaflet; and to bring the PI in line with the latest QRD template version 10.4

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.18. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) - FLUCELVAX (CAP) - EMEA/H/C/006532/II/0001

Applicant: Seqirus Netherlands B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Extension of indication to include treatment of children from 6 months of age and older for FLUCELVAX, based on results from study V130_14. This is a Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP is also being submitted.
In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the MAH took the opportunity to implement changes to sections 4.4 and 4.5 of the SmPC

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.19. Ivosidenib - TIBSOVO (CAP) - EMEA/H/C/005936/II/0012, Orphan

Applicant: Les Laboratoires Servier

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Submission of an updated RMP version 2.1 for TIBSOVO and a replacement study protocol for study S095031-218. This is a phase 1, multicenter, open-label, safety and pharmacokinetic study of orally administered ivosidenib in participants with IDH1-mutated malignancies and hepatic or renal impairment. Study milestones in RMP were updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.20. Ixekizumab - TALTZ (CAP) - EMEA/H/C/003943/II/0053

Applicant: Eli Lilly and Co (Ireland) Limited

PRAC Rapporteur: Gabriele Maurer

Scope: Extension of indication to include treatment of juvenile idiopathic arthritis for TALTZ, based on week 16 results from study I1F-MC-RHCG; this is a multicenter, open-label, efficacy, safety, tolerability, and pharmacokinetic study (COSPIRIT-JIA) of subcutaneous ixekizumab with adalimumab reference arm, in children from 2 to less than 18 years of age with juvenile idiopathic arthritis subtypes of enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis was performed to evaluate the efficacy and safety of ixekizumab for 16 weeks after treatment initiation. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted. Furthermore, the PI is in line with the latest QRD template version 10.4

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. L-lysine hydrochloride, L-arginine hydrochloride - LYSAKARE (CAP) - EMEA/H/C/004541/II/0018

Applicant: Advanced Accelerator Applications

PRAC Rapporteur: Adam Przybylkowski

Scope: Update of sections 4.2, 4.3, 4.4, 4.8 and 5.1 of the SmPC in order to remove the contraindication and update the warning on 'Hyperkalaemia' as well as on 'Metabolic acidosis' and to update safety information based on final results from study CAAA001A12401 listed as a category 3 study in the RMP. This is a multicenter, open-label post authorization safety study to evaluate the effect of LysaKare infusion on serum potassium levels in GEP-NET patients eligible for Lutathera treatment. The RMP version 3.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Lenacapavir - SUNLENCA (CAP) - EMEA/H/C/005638/II/0022/G

Applicant: Gilead Sciences Ireland Unlimited Company

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Grouping of two type II variations:
- Update of section 5.1 of the SmPC to include efficacy and resistance data based on week 156 interim data from Study GS-US-200-4625; a phase 2/3 study to evaluate the safety and efficacy of long-acting capsid inhibitor GS-6207 in combination with an optimized background regimen in heavily treatment experienced people living with HIV-1 infection with multidrug resistance (category 3 study in the RMP). Additionally, upon request by the CHMP following the assessment of II/0013, the MAH proposes to update section 4.8 of the SmPC to include information related to injection site nodules and induration that were non-resolved at the end of follow-up.
- Provision of the final study report of Study GS-US-200-4334: a phase 2 randomized, open label, active controlled study evaluating the safety and efficacy of long-acting capsid inhibitor GS-6207 in combination with other antiretroviral agents in people living with HIV (category 3 study in the RMP).

An updated RMP version 2.1 was included as part of the application

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Lenvatinib - KISPLYX (CAP) - EMEA/H/C/004224/II/0061

Applicant: Eisai GmbH

PRAC Rapporteur: David Olsen

Scope: Submission of the final report from study E7080-G000-307 listed as a category 3 study in the RMP. This is a multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma. The RMP version 18.0 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.24. Lutetium (^{177}Lu) oxodotreotide - LUTATHERA (CAP) - EMEA/H/C/004123/II/0058, Orphan

Applicant: Advanced Accelerator Applications

PRAC Rapporteur: Adam Przybylkowski

Scope: Extension of indication to include the treatment of unresectable or metastatic, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adolescents aged 12 years and older for LUTATHERA based on primary analysis results from study CAAA601A32201 (also referred to as NETTER-P) as well as results from modelling and simulation analysis of PK and dosimetry data of Lutathera in adolescents. NETTER-P study is a Phase II, multicenter open-label study which evaluated the safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and pheochromocytoma and paragangliomas (PPGLs). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 11 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.25. Maralixibat - LIVMARLI (CAP) - EMEA/H/C/005857/X/0016, Orphan

Applicant: Mirum Pharmaceuticals International B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Extension application to add a new strength (19 mg/ml oral solution). In addition, the MAH took the opportunity to implement editorial changes in sections 4.2 and 4.8. of the SmPC and Point 4 of PL of Livmarli, 9.5 mg/ml oral solution

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.26. Mitapivat - PYRUKYND (CAP) - EMEA/H/C/005540/X/0010/G, Orphan

Applicant: Agios Netherlands B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Extension application to introduce a new strength (100 mg film-coated tablet) associated with a new orphan indication for the "treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassaemia". The extension application is grouped with a type II quality variation (C.I.4) to update of sections 4.2 and 5.2 of the SmPC in order to update pharmacokinetic information based on final results from study AG348-C-024 listed as a category 3 study in the RMP; this is a Phase 1, Open-label, Single-dose, Pharmacokinetic Study of Mitapivat in Subjects with Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects with Normal Hepatic Function. The RMP (version 1.1) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.27. Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/II/0150

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Gabriele Maurer

Scope: Update of sections 4.2 and 4.4 of the SmPC in order to modify administration instructions to add the option for self-administration or administration by a caregiver and to

update educational guidance, based on supportive data including final results from study 101MS330; this is a Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab Administered to Japanese Participants With Relapsing-Remitting Multiple Sclerosis via a Subcutaneous Route of Administration. The Annex II, Labelling and Package Leaflet are updated accordingly. The RMP version 32.1 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.28. Niraparib - ZEJULA (CAP) - EMEA/H/C/004249/II/0056, Orphan

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Jan Neuhauser

Scope: Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from PRIMA study (PR-30-5017-C) listed as a PAES in the Annex II; this is a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. The RMP version 9.0 has also been submitted. In addition, the MAH took the opportunity to update section D of Annex II, and to implement editorial changes to the PI

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.29. Odevixibat - BYLVAY (CAP) - EMEA/H/C/004691/II/0022/G, Orphan

Applicant: Ipsen Pharma

PRAC Rapporteur: Adam Przybylkowski

Scope: A grouped application including two type II variations:
- Update of sections 4.2, 4.4, 4.8, and 5.1 of the SmPC based on the clinical study report for the completed 72 weeks of Study A4250-008; an open-label, phase III study to evaluate the long-term efficacy and safety of odevixibat in children with PFIC (category 3 study in the RMP; MEA 002).
The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and the Package Leaflet. An updated RMP version 6.1 is included in this submission.
- Submission of the clinical study report for Study A4250-J001; a Phase I PK study in healthy Japanese adult male patients

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.30. Odevixibat - KAYFANDA (CAP) - EMEA/H/C/006462/II/0001/G

Applicant: Ipsen Pharma

PRAC Rapporteur: Adam Przybylkowski

Scope: A grouped application consisting of:
C.I.4: Update of sections 4.4, 4.8, and 5.1 of the SmPC based on results from Study A4250-015 listed as a category 3 study in the RMP; this is a Phase 3, multicentre, open-label extension study to evaluate the long-term safety and efficacy of odevixibat in patients with

ALGS. The Package Leaflet is updated accordingly. The RMP version 6.2 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI.

C.I.13: Submission of the 72 week report from study A4250-008. This is a Phase 3, multicentre, open-label extension study to investigate the long-term efficacy and safety of odevixibat in patients with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.31. Ponesimod - PONVORY (CAP) - EMEA/H/C/005163/II/0018/G

Applicant: Laboratoires Juvise Pharmaceuticals

PRAC Rapporteur: Karin Erneholm

Scope: Grouped application comprised of two Type II Variations, as follows:

C.I.13: Submission of the final report from study AC-058B202; this is a Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of 10, 20, and 40 mg/day Ponesimod, an Oral S1P1 Receptor Agonist, in Patients with Relapsing-remitting Multiple Sclerosis.

C.I.13: Submission of the final report from study AC-058B303 (OPTIMUM-LT); this is a Multicenter, Non-Comparative Extension to Study AC-058B301, to Investigate the Long-Term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects with Relapsing Multiple Sclerosis.

The RMP version 4.1 has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.32. Tisagenlecleucel - KYMRIAH (CAP) - EMEA/H/C/004090/II/0092, Orphan

Applicant: Novartis Europharm Limited, ATMP

PRAC Rapporteur: Gabriele Maurer

Scope: Update of section 4.2 of the SmPC in order to update the 'monitoring after infusion' recommendations, based on existing clinical trial data as well as literature references reporting real word experience. The Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to introduce a minor change to the HCP educational programme in the Annex II in order to enhance readability

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.3.33. Tislelizumab - TEVIMBRA (CAP) - EMEA/H/C/005919/II/0018

Applicant: Beigene Ireland Limited

PRAC Rapporteur: Bianca Mulder

Scope: Extension of indication for Tevimbra in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable NSCLC based on interim results from study BGB-A317-315. Study BGB-A317-315 is a phase 3 randomized, placebo-controlled, double-blind study to compare the efficacy and safety of neoadjuvant treatment with tislelizumab plus platinum-based doublet chemotherapy followed by adjuvant tislelizumab versus neoadjuvant treatment with placebo plus platinum-based doublet chemotherapy followed by adjuvant placebo in patients with resectable Stage II or IIIA NSCLC. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.7 of the RMP has also been submitted

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

6. Periodic safety update reports (PSURs)

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

6.1.1. Aflibercept[3] - ZALTRAP (CAP) - PSUSA/00010019/202408

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.2. Agalsidase alfa - REPLAGAL (CAP) - PSUSA/00000069/202408

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.3. Alirocumab - PRALUENT (CAP) - PSUSA/00010423/202407

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

[3] Oncological indication(s) only

6.1.4. Avalglucosidase alfa - NEXVIADYME (CAP) - PSUSA/00011002/202408

Applicant: Sanofi B.V.

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.5. Bimekizumab - BIMZELX (CAP) - PSUSA/00010953/202408

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.6. Brodalumab - KYNTHEUM (CAP) - PSUSA/00010616/202407

Applicant: LEO Pharma A/S

PRAC Rapporteur: Monica Martinez Redondo

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.7. Ciltacabtagene autoleucel - CARVYKTI (CAP) - PSUSA/00011000/202408

Applicant: Janssen-Cilag International NV, ATMP

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.8. Dengue tetravalent vaccine (live, attenuated) - DENGUE TETRAVALENT VACCINE (LIVE, ATTENUATED) TAKEDA (Art 58[4]) - EMEA/H/W/005362/PSUV/0019

Applicant: Takeda GmbH

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUR procedure

Action: For adoption of recommendation to CHMP

[4] Article 58 of Regulation (EC) No 726/2004 allows the Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO) on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU)

6.1.9. Dengue tetravalent vaccine[5] (live, attenuated) - QDENGA (CAP) - PSUSA/00011034/202408

Applicant: Takeda GmbH

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.10. Difelikefalin - KAPRUVIA (CAP) - PSUSA/00010995/202408

Applicant: Vifor Fresenius Medical Care Renal Pharma France

PRAC Rapporteur: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.11. Efanesoctocog alfa - ALTUVOCT (CAP) - PSUSA/00011062/202408

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.12. Elranatamab - ELREXFIO (CAP) - PSUSA/00000225/202408

Applicant: Pfizer Europe Ma EEIG

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.13. Eravacycline - XERAVA (CAP) - PSUSA/00010718/202408

Applicant: Paion Pharma GmbH

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.14. Fedratinib - INREBIC (CAP) - PSUSA/00010909/202408

Applicant: Bristol-Myers Squibb Pharma EEIG

[5] Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated / Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated / Dengue virus, serotype 2, live, attenuated

PRAC Rapporteur: Sonja Hrabcik

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.15. Fosdenopterin - NULIBRY (CAP) - PSUSA/00011017/202408

Applicant: TMC Pharma (EU) Limited

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.16. Idelalisib - ZYDELIG (CAP) - PSUSA/00010303/202407

Applicant: Gilead Sciences Ireland UC

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.17. Idursulfase - ELAPRASE (CAP) - PSUSA/00001722/202407

Applicant: Takeda Pharmaceuticals International AG Ireland Branch

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.18. Imlifidase - IDEFIRIX (CAP) - PSUSA/00010870/202408

Applicant: Hansa Biopharma AB

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.19. Interferon beta-1b - BETAFERON (CAP); EXTAVIA (SRD) (CAP) - PSUSA/00001759/202407

Applicant: Bayer AG (Betaferon), Novartis Europharm Limited (Extavia (SRD))

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.20. Lefamulin - XENLETA (CAP) - PSUSA/00010872/202408

Applicant: Nabriva Therapeutics Ireland DAC

PRAC Rapporteur: Eva Jirsová

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.21. Lenacapavir - SUNLENCA (CAP) - PSUSA/00011012/202408

Applicant: Gilead Sciences Ireland Unlimited Company

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.22. Linaclotide - CONSTELLA (CAP) - PSUSA/00010025/202408

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.23. Lipegfilgrastim - LONQUEX (CAP) - PSUSA/00010111/202407

Applicant: Teva B.V.

PRAC Rapporteur: Terhi Lehtinen

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.24. Lisocabtagene maraleucel - BREYANZI (CAP) - PSUSA/00010990/202408

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.25. Lonapegsomatropin - SKYTROFA (CAP) - PSUSA/00010969/202408

Applicant: Ascendis Pharma Endocrinology Division A/S

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.26. Melphalan flufenamide - PEPAXTI (CAP) - PSUSA/00011013/202408

Applicant: Oncopeptides AB

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.27. Mitapivat - PYRUKYND (CAP) - PSUSA/00011025/202408

Applicant: Agios Netherlands B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.28. Natalizumab - TYRUKO (CAP); TYSABRI (CAP) - PSUSA/00002127/202408

Applicant: Sandoz GmbH (Tyruko), Biogen Netherlands B.V. (Tysabri)

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.29. Omaveloxolone - SKYCLARYS (CAP) - PSUSA/00000245/202408

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.30. Patisiran - ONPATTRO (CAP) - PSUSA/00010715/202408

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.31. Peginterferon beta-1A - PLEGRIDY (CAP) - PSUSA/00010275/202407

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Karin Bolin

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.32. Pioglitazone - ACTOS (CAP); glimepiride, pioglitazone - TANDEMACT (CAP); metformin, pioglitazone - COMPETACT (CAP); - PSUSA/00002417/202407

Applicant: CHEPLAPHARM Arzneimittel GmbH

PRAC Rapporteur: Eamon O'Murchu

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.33. Pretomanid - DOVPRELA (CAP) - PSUSA/00010863/202408

Applicant: Mylan IRE Healthcare Limited

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.34. Risdiplam - EVRYSDI (CAP) - PSUSA/00010925/202408

Applicant: Roche Registration GmbH

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.35. Saxagliptin, dapagliflozin - QTERN (CAP) - PSUSA/00010520/202407

Applicant: AstraZeneca AB

PRAC Rapporteur: Amelia Cupelli

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.36. Sotrovimab - XEVUDY (CAP) - PSUSA/00010973/202408

Applicant: Glaxosmithkline Trading Services Limited

PRAC Rapporteur: Liana Martirosyan

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.37. Sparsentan - FILSPARI (CAP) - PSUSA/00011060/202408

Applicant: Vifor France

PRAC Rapporteur: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.38. Sutimlimab - ENJAYMO (CAP) - PSUSA/00011023/202408

Applicant: Sanofi B.V.

PRAC Rapporteur: Jan Neuhauser

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.39. Talquetamab - TALVEY (CAP) - PSUSA/00000099/202408

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.40. Teclistamab - TECVAYLI (CAP) - PSUSA/00011010/202408

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Jana Lukacisinova

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.41. Tisagenlecleucel - KYMRIAH (CAP) - PSUSA/00010702/202408

Applicant: Novartis Europharm Limited, ATMP

PRAC Rapporteur: Gabriele Maurer

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.42. Upadacitinib - RINVOQ (CAP) - PSUSA/00010823/202408

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Petar Mas

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.43. Valoctocogene roxaparvovec - ROCTAVIAN (CAP) - PSUSA/00011009/202408

Applicant: BioMarin International Limited, ATMP

PRAC Rapporteur: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CAT and CHMP

6.1.44. Vosoritide - VOXZOGO (CAP) - PSUSA/00010952/202408

Applicant: BioMarin International Limited

PRAC Rapporteur: Zane Neikena

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.1.45. Voxelotor - OXBRYTA (CAP) - PSUSA/00010983/202408

Applicant: Pfizer Europe Ma EEIG

PRAC Rapporteur: Jo Robays

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CHMP

6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

None

6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only

6.3.1. Alprostadil[6] (NAP) - PSUSA/00010021/202407

Applicant(s): various

PRAC Lead: Sonja Hrabcik

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[6] Indicated for patency of the ductus arteriosus only

6.3.2. Amlodipine, rosuvastatin (NAP); amlodipine, perindopril, rosuvastatin (NAP) - PSUSA/00010434/202407

Applicant(s): various

PRAC Lead: Melinda Palfi

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.3. Anastrozole (NAP) - PSUSA/00000210/202408

Applicant(s): various

PRAC Lead: Zane Neikena

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.4. Benperidol (NAP) - PSUSA/00000329/202407

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.5. Bibrocathol (NAP) - PSUSA/00000406/202408

Applicant(s): various

PRAC Lead: Karin Bolin

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.6. Budesonide, salmeterol (NAP) - PSUSA/00010511/202407

Applicant(s): various

PRAC Lead: Bianca Mulder

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.7. Chlorocresol, chlorhexidine, hexamidine (NAP) - PSUSA/00001603/202408

Applicant(s): various

PRAC Lead: Zoubida Amimour

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.8. Cinchocaine hydrochloride, hydrocortisone (NAP) - PSUSA/00000761/202408

Applicant(s): various

PRAC Lead: John Joseph Borg

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.9. Everolimus[7] (NAP) - PSUSA/00010269/202407

Applicant(s): various

PRAC Lead: Mari Thorn

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.10. Lactobacillus all subspecies and combinations of subspecies (NAP) - PSUSA/00010598/202407

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.11. Lidocaine hydrochloride, phenylephrine hydrochloride, tropicamide (NAP) - PSUSA/00010390/202407

Applicant(s): various

PRAC Lead: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.12. Magnesium sulfate, sodium sulfate, potassium sulfate (NAP) - PSUSA/00010239/202408

Applicant(s): various

PRAC Lead: Jana Lukacisinova

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

[7] Indicated for rejection of transplanted organs only

6.3.13. Montelukast (NAP) - PSUSA/00002087/202407

Applicant(s): various

PRAC Lead: Kimmo Jaakkola

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.14. Naphazoline (NAP); naphazoline, zinc sulphate (NAP) - PSUSA/00010571/202407

Applicant(s): various

PRAC Lead: Karin Erneholm

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.15. Neomycin, triamcinolone (NAP) - PSUSA/00000081/202408

Applicant(s): various

PRAC Lead: Eva Jirsova

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.3.16. Tiapride (NAP) - PSUSA/00002944/202407

Applicant(s): various

PRAC Lead: Tiphaine Vaillant

Scope: Evaluation of a PSUSA procedure

Action: For adoption of recommendation to CMDh

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Eculizumab - SOLIRIS (CAP) - EMEA/H/C/000791/LEG 064.1

Applicant: Alexion Europe SAS

PRAC Rapporteur: Monica Martinez Redondo

Scope: MAH response to PSUR#19 (EMEA/H/C/PSUSA/00001198/202310) as adopted in October 2024

From PSURx (EMEA/H/C/PSUSA/00001198/202310 - #19
The MAH for Soliris is requested, to provide cumulative data from all the available sources in a tabulated format for all the hepatotoxicity cases (irrespective of whether, according to the MAH, they have alternative aetiologies) with transaminases elevation and clinical consequences, reported with eculizumab until de DLP of this PSUR

Action: For adoption of advice to CHMP

6.4.2. Nonacog beta pegol - REFIXIA (CAP) - EMEA/H/C/004178/LEG 009

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Gabriele Maurer

Scope: From PSUSA/00010608/202305
Response to the Rapporteur's assessment comment which was received on 11-Jan-2024 in the Final PRAC assessment report for the Refixia PSUR covering the period (01/06/2022 to 31/05/2023) concerning motor developmental delay and speech disorder

Action: For adoption of advice to CHMP

6.4.3. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/LEG 058

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Rhea Fitzgerald

Scope: From PSUSA/00003085/202312
The MAH should address the questions raised in the PSUSA regarding severe depression/ suicidal ideation

Action: For adoption of advice to CHMP

6.4.4. Vildagliptin - GALVUS (CAP) - EMEA/H/C/000771/LEG 050

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Mari Thorn

Scope: From PSUSA/00003113/202402
MAH Response to PSUSA/00003113/202402 assessment report of October 2024:
The MAH is requested a cumulative review of all cases of Severe Cutaneous Adverse Reactions MedDRA SMQ broad level, with DRESS, SJS and TEN cases associated with vildagliptin as suspect drug

Action: For adoption of advice to CHMP

6.4.5. Vildagliptin - JALRA (CAP) - EMEA/H/C/001048/LEG 034

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Mari Thorn

Scope: From PSUSA/00003113/202402
MAH Response to PSUSA/00003113/202402 assessment report of October 2024:The MAH is requested a cumulative review of all cases of Severe Cutaneous Adverse Reactions MedDRA SMQ broad level, with DRESS, SJS and TEN cases associated with vildagliptin as suspect drug

Action: For adoption of advice to CHMP

6.4.6. Vildagliptin - XILIARX (CAP) - EMEA/H/C/001051/LEG 034

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Mari Thorn

Scope: From PSUSA/00003113/202402
MAH Response to PSUSA/00003113/202402 assessment report of October 2024:The MAH is requesteda cumulative review of all cases of Severe Cutaneous Adverse Reactions MedDRA SMQ broad level, with DRESS, SJS and TEN cases associated with vildagliptin as suspect drug

Action: For adoption of advice to CHMP

6.4.7. Vildagliptin, metformin hydrochloride - EUCREAS (CAP) - EMEA/H/C/000807/LEG 028

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Mari Thorn

Scope: From PSUSA/00003113/202402
MAH Response to PSUSA/00003113/202402 assessment report of October 2024:The MAH is requested days a cumulative review of all cases of Severe Cutaneous Adverse Reactions MedDRA SMQ broad level, with DRESS, SJS and TEN cases associated with vildagliptin as suspect drug

Action: For adoption of advice to CHMP

6.4.8. Vildagliptin, metformin hydrochloride - ICANDRA (CAP) - EMEA/H/C/001050/LEG 026

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Mari Thorn

Scope: From PSUSA/00003113/202402
MAH Response to PSUSA/00003113/202402 assessment report of October 2024:The MAH is requested a cumulative review of all cases of Severe Cutaneous Adverse Reactions MedDRA SMQ broad level, with DRESS, SJS and TEN cases associated with vildagliptin as suspect drug

Action: For adoption of advice to CHMP

6.4.9. Vildagliptin, metformin hydrochloride - ZOMARIST (CAP) - EMEA/H/C/001049/LEG 026

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Mari Thorn

Scope: From PSUSA/00003113/202402
MAH Response to PSUSA/00003113/202402 assessment report of October 2024:
The MAH is requested a cumulative review of all cases of Severe Cutaneous Adverse Reactions MedDRA SMQ broad level, with DRESS, SJS and TEN cases associated with vildagliptin as suspect drug

Action: For adoption of advice to CHMP

6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. Blinatumomab - BLINCYTO (CAP) - EMEA/H/C/003731/II/0054, Orphan

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Jana Lukacisinova

Scope: To update sections 4.2, 4.4, 4.8 of the SmPC to include Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS); and to update section D of Annex II to remove educational materials for physicians, pharmacists and nurses and to include ICANS within neurologic events in educational material for patient/caregivers and patient alert card following the outcome of PSUR procedure EMEA/H/C/PSUSA/00010460/202212. The Package Leaflet is updated accordingly. The RMP version 17.0 has also been submitted

Action: For adoption of PRAC Assessment Report

6.6. Expedited summary safety reviews[8]

None

7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)[9]

None

[8] Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC
[9] In accordance with Article 107n of Directive 2001/83/EC

7.2. Protocols of PASS non-imposed in the marketing authorisation(s)[10]

7.2.1. Brexucabtagene autoleucel - TECARTUS (CAP) - EMEA/H/C/005102/ANX 002.6

Applicant: Kite Pharma EU B.V., ATMP

PRAC Rapporteur: Bianca Mulder

Scope: Response to MEA 002.5:
Revised Protocol #5 for Study KTE-EU-472-6036
Title: Long-term, non-interventional study of recipients of Tecartus (brexucabtagene autoleucel) for treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL)

Action: For adoption of advice to CAT and CHMP

7.2.2. Danicopan - VOYDEYA (CAP) - EMEA/H/C/005517/MEA 002.1

Applicant: Alexion Europe

PRAC Rapporteur: Martin Huber

Scope: ***Revised Protocol Study ALX-PNH-502***
Title: An observational cohort study to assess long-term safety of danicopan add-on therapy in patients with paroxysmal nocturnal hemoglobinuria: analysis of IPIG-registry data

Action: For adoption of advice to CHMP

7.2.3. Efanesoctocog alfa - ALTUVOCT (CAP) - EMEA/H/C/005968/MEA 002

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Amelia Cupelli

Scope: From initial MAA
PASS Protocol (non-imposed)
Observational registry study in Previously Untreated Patients (PUPs) with Haemophilia A (ATHN)

Action: For adoption of advice to CHMP

7.2.4. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/MEA 007.3

Applicant: Argenx

PRAC Rapporteur: Rhea Fitzgerald

Scope: MAH's responses to MEA 007.2 [***Revised Protocol***] as adopted in October 2024.
A revised protocol for the non-imposed non-interventional PASS to Evaluate the Risk of Malignancies in Patients with Myasthenia Gravis (MG) Treated with Efgartigimod should be submitted by 19/12/2024 taking into account the comments included in section 8 8.

[10] In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004

Conclusion following assessment of MAH responses to 2nd RSI in the PRAC AR for EMEA/H/C/005849/MEA/007.2

Action: For adoption of advice to CHMP

7.2.5. Exagamglogene autotemcel - CASGEVY (CAP) - EMEA/H/C/005763/MEA 011.1

Applicant: Vertex Pharmaceuticals (Ireland) Limited, ATMP

PRAC Rapporteur: Bianca Mulder

Scope: From intial MAA
Revised Protocol Version 2.0 for PASS no. VX24-290-102
Title: Healthcare Professional Survey (HCP) to Assess the Effectiveness of the Additional Risk Minimization Measures (aRMM) for Casgevy (exagamglogene autotemcel)

Action: For adoption of advice to CAT and CHMP

7.2.6. Fenfluramine - FINTEPLA (CAP) - EMEA/H/C/003933/MEA 005.6

Applicant: UCB Pharma SA

PRAC Rapporteur: Martin Huber

Scope: ***Protocol amendment (version 6.0) / Study (EP0219 [former ZX008-2102])***
Post Authorisation Safety Study (PASS): A Drug Utilisation Study of Fenfluramine In Europe (DUS)

Action: For adoption of advice to CHMP

7.2.7. Omaveloxolone - SKYCLARYS (CAP) - EMEA/H/C/006084/MEA 002.2

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Amelia Cupelli

Scope: From initial MAA
Revised Protocol for PASS 296FA401 (408-C-2301)
An observational, multinational, post-marketing registry of omaveloxolone-treated patients with Friedreich's ataxia)

Action: For adoption of advice to CHMP

7.3. Results of PASS imposed in the marketing authorisation(s)[11]

None

[11] In accordance with Article 107p-q of Directive 2001/83/EC

7.4. Results of PASS non-imposed in the marketing authorisation(s)[12]

7.4.1. Brigatinib- ALUNBRIG (CAP) - EMEA/H/C/004248/II/0056

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Carla Torre

Scope: Submission of the final report from Brigatinib-5007 study listed as a category 3 study in the RMP. This is a non-interventional cohort study to provide real-world evidence of the occurrence of early-onset pulmonary events in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer treated with brigatinib: a post-authorisation safety study. The RMP version 7 has also been submitted. The MAH proposes the removal of the additional risk minimization measure, the Alunbrig Patient Alert Card (PAC), for the risk of early-onset pulmonary events (EOPEs). In addition, the MAH took the opportunity to introduce editorial changes to the PI

Action: For adoption of PRAC Assessment Report

7.4.2. Cinacalcet - MIMPARA (CAP) - EMEA/H/C/000570/II/0076

Applicant: Amgen Europe B.V.

PRAC Rapporteur: Mari Thorn

Scope: Submission of the final report from study 20180204 listed as a category 3 study in the RMP. This is a non-interventional observational registry study to evaluate the use and safety of cinacalcet among paediatric patients with secondary hyperparathyroidism (HPT)

Action: For adoption of PRAC Assessment Report

7.4.3. Ertugliflozin, metformin hydrochloride - SEGLUROMET (CAP) - EMEA/H/C/004314/WS2794/0026; Ertugliflozin - STEGLATRO (CAP) - EMEA/H/C/004315/WS2794/0025; Ertugliflozin, sitagliptin - STEGLUJAN (CAP) - EMEA/H/C/004313/WS2794/0029

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Bianca Mulder

Scope: Submission of the final report from study 8835-062 listed as a category 3 study in the RMP for Steglatro, Steglujan and Segluromet. This is a non-interventional post-authorization safety study (PASS) to assess the risk of diabetic ketoacidosis (DKA) among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycemic agents. The RMP version 2.3 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.4. Esketamine - SPRAVATO (CAP) - EMEA/H/C/004535/II/0026

Applicant: Janssen-Cilag International N.V.

[12] In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013

PRAC Rapporteur: Terhi Lehtinen

Scope: Submission of the final study report for the non-interventional study PCSNSP002812 listed as a category 3 study in the RMP. This is a survey in order to assess the effectiveness of SPRAVATO educational materials for additional risk minimization measures in the European Union. The RMP version 8.1 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.5. Ibrutinib - IMBRUVICA (CAP) - EMEA/H/C/003791/II/0093

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: Submission of the study report for additional pharmacovigilance analysis to further evaluate the risk of haemorrhage in participants receiving ibrutinib and concomitant vitamin K antagonists with or without antiplatelet drugs, listed as a category 3 study in the RMP

Action: For adoption of PRAC Assessment Report

7.4.6. Niraparib - ZEJULA (CAP) - EMEA/H/C/004249/II/0058, Orphan

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Jan Neuhauser

Scope: Submission of the final report from study 3000-04-001/ GSK213705 listed as a category 3 study in the RMP; this is a non-interventional PASS to evaluate the risks of myelodysplastic syndrome/acute myeloid leukaemia and second primary malignancies in adult patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer receiving maintenance treatment with Zejula. The RMP version 10.0 has also been submitted

Action: For adoption of PRAC Assessment Report

7.4.7. Nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/II/0149

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Gabriele Maurer

Scope: Submission of the final clinical study report (CSR) for the PASS study CA209234 listed as a category 3 study in the RMP. This is an observational, multicenter, prospective study in patients treated with nivolumab for melanoma and lung cancer in order assess the safety experience, survival, adverse event management, and outcomes of adverse events associated with nivolumab (monotherapy or with ipilimumab) in routine oncology care facilities. The RMP version 42.0 has also been submitted.

Action: For adoption of PRAC Assessment Report

7.4.8. Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - MOSQUIRIX (Art 58[13]) - EMEA/H/W/002300/II/0085/G

Applicant: GlaxoSmithkline Biologicals SA

PRAC Rapporteur: Jean-Michel Dogné

Scope: A grouped application comprised of two type II variations, as follows:

C.I.4: Update of sections 4.4 and 5.1 of the SmPC in order to remove meningitis from the list of important potential risks and add effectiveness data based on EPI-MAL-003 study listed as a category 3 study in the RMP. This is a prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa countries. The Package Leaflet is updated accordingly.
The RMP version 6.0 has also been submitted.

C.I.13: Submission of the final report from study MVPE (Malaria Vaccine Pilot Evaluation) listed as a category 3 study in the RMP. This is a observational study in the context of a cluster-randomized pilot implementation in order to assess the feasibility of delivery, safety, and impact on mortality of the RTS,S/AS01E malaria vaccine delivered through the routine immunization services in Kenya, Malawi, and Ghana over 4 years

Action: For adoption of PRAC Assessment Report

7.4.9. Trifluridine, tipiracil - LONSURF (CAP) - EMEA/H/C/003897/II/0031

Applicant: Les Laboratoires Servier

PRAC Rapporteur: Mari Thorn

Scope: Submission of the final report from study DIM-95005-001 (PROMETCO), listed as a category 3 PASS in the RMP. This is a non-interventional, observational, real world evidence prospective cohort study in the management of metastatic colorectal cancer. The RMP version 11.1 has also been submitted as the missing information "Use in patients in worse condition than ECOG 0-1" has been removed based on the results from PROMETCO. The PART II - section SVII 1 & SVII 2 has been updated to comply with GVP module V revision 2

Action: For adoption of PRAC Assessment Report

7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

7.5.1. Cabotegravir - APRETUDE (CAP) - EMEA/H/C/005756/MEA 002.1

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: From initial MAA
First Interim Report for PASS No 215325

[13] Article 58 of Regulation (EC) No 726/2004 allows the Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO) on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU)

Antiretroviral Pregnancy Registry (APR) to monitor CAB LA PrEP use in Pregnancy
The APR is an international registry that monitors prenatal exposures to antiretroviral (ARV) drugs to detect a potential increase in the risk of birth defects through a prospective exposure registration cohort. The registry's primary objective is to monitor for birth defects among ARV exposed pregnancies. The registry has been monitoring pregnancies with prenatal exposure to ARVs used for PrEP since the approval of ARVs used in oral PrEP.

The APR is a MAH-sponsored study involving the collaborative effort of multiple companies. Data from the APR will assess maternal (pregnancy outcomes, abortions, still births) and foetal outcomes (premature births and low birth weight) following CAB LA PrEP use during pregnancy. Exposure to CAB LA PrEP relative to gestation period and conception will be captured in the registry, thus enabling assessment of pre-conception exposures along with first, second and third trimester exposures

Action: For adoption of advice to CHMP

7.5.2. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 006.5

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: From initial MAA
RMP Category 3: Study No 215325
Pregnancy and Neonatal Outcomes following Prenatal Exposure to Cabotegravir: Data from The Antiretroviral Pregnancy Registry (APR).
2ND INTERIM REPORT

Action: For adoption of advice to CHMP

7.5.3. Efgartigimod alfa - VYVGART (CAP) - EMEA/H/C/005849/MEA 004.3

Applicant: Argenx

PRAC Rapporteur: Rhea Fitzgerald

Scope: From Initial MAA:
First Interim Report for PASS to characterize the missing information on use in pregnant woman outlined in the risk management plan

Action: For adoption of advice to CHMP

7.5.4. Filgotinib - JYSELECA (CAP) - EMEA/H/C/005113/MEA 016.4

Applicant: Alfasigma S.p.A.

PRAC Rapporteur: Petar Mas

Scope: From II/0001:
Annual Interim Report for Study GLPG0634-CL-413
Title: Non-interventional, post-authorization safety study of filgotinib in patients with moderately to severely active ulcerative colitis (a European multi registry-based study)

Action: For adoption of advice to CHMP

7.5.5. Filgotinib - JYSELECA (CAP) - EMEA/H/C/005113/MEA 019

Applicant: Alfasigma S.p.A.

PRAC Rapporteur: Petar Mas

Scope: From initial MAA
Interim report for PASS GLPG0634-CL-403:
Non-interventional post-authorization safety study of filgotinib in the treatment of patients with moderate to severe active rheumatoid arthritis within European registries, including:
Study GS-EU-417-9046: RABBIT (MEA002)
Study GS-EU-417-9047: ARTIS (MEA 003)
Study GS-EU-417-9048: BSRBR-RA (MEA 004)
Study GS-EU-417-5882: BIOBADASER (MEA 005)
Study GS-EU-417-5883: DANBIO (MEA 006)

Action: For adoption of advice to CHMP

7.5.6. Fingolimod - GILENYA (CAP) - EMEA/H/C/002202/MEA 038.8

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Tiphaine Vaillant

Scope: From X-0044-G
5th Interim Report for Study CFTY720D2311
A two-year, double-blind, randomized, multicenter, active-controlled Core Phase study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension Phase

Action: For adoption of advice to CHMP

7.5.7. Galcanezumab - EMGALITY (CAP) - EMEA/H/C/004648/MEA 004.3

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Terhi Lehtinen

Scope: From initial MAA
Interim Study Report for I5Q-MC-B001
A Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in US Patients in the Course of Routine Clinical Care

Action: For adoption of advice to CHMP

7.5.8. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - EMEA/H/C/005269/MEA 002.7

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Martin Huber

Scope: 4th Annual Interim Study Report for PASS VX20-445-120
Title: Real-World Effects and Utilisation Patterns of Elexacaftor, Tezacaftor, and Ivacaftor Combination Therapy (ELX/TEZ/IVA) in Patients with Cystic Fibrosis (CF)

Action: For adoption of advice to CHMP

7.5.9. Ozanimod - ZEPOSIA (CAP) - EMEA/H/C/004835/MEA 001.4

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Maria del Pilar Rayon

Scope: From initial MAA
First Interim Report for PASS IM047-009 (ORION)
Ozanimod real-world safety – a post-authorisation multi-national long-term non-interventional study

Action: For adoption of advice to CHMP

7.5.10. Plasmodium falciparum and hepatitis b vaccine (recombinant, adjuvanted) - MOSQUIRIX (Art 58[14]) - EMA/PAM/0000242605

Applicant: GlaxoSmithKline Biologicals

PRAC Rapporteur: Jean-Michel Dogné

Scope: Submission of the interim analysis report for the study EPI-MAL-010: A phase IV, longitudinal, cross-sectional, retrospective, ancillary epidemiology study of the EPI-MAL-005 study to evaluate the genetic diversity in the Plasmodium falciparum parasite circumsporozoite sequences before and after the implementation of the RTS,S/AS01E vaccine in malaria-positive subjects ranging from 6 months to less than 5 years of age, together with updated statistical analysis plan (SAP)

Action: For adoption of advice to CHMP

7.5.11. Somatrogon - NGENLA (CAP) - EMEA/H/C/005633/MEA 001.3

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Martirosyan

Scope: From Initial MAA:
1st Interim Report PASS C0311023
An Active Surveillance PASS to Monitor the Real-World Long-term Safety of Somatrogon Among Paediatric Patients in Europe to estimate the incidence rates of neoplasms, diabetes mellitus type 2, and the clinical endpoints related to immunogenicity, and medication errors in paediatric patients treated with somatrogon, and paediatric patients treated with once daily somatropin, in the course of routine clinical care

Action: For adoption of advice to CHMP

[14] Article 58 of Regulation (EC) No 726/2004 allows the Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO) on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU)

7.5.12. Talimogene laherparepvec - IMLYGIC (CAP) - EMEA/H/C/002771/MEA 005.3

Applicant: Amgen Europe B.V., ATMP

PRAC Rapporteur: Gabriele Maurer

Scope: 6th Interim Report for PASS 20130193
A post-marketing, prospective cohort study of patients treated with talimogene laherparepvec in clinical practice to characterize the risk of herpetic illness among patients, close contacts, and healthcare providers; and long term safety in treated patients.

Annual interim reports to be included in the PSUR and DSUR

Action: For adoption of advice to CAT and CHMP

7.5.13. Tildrakizumab - ILUMETRI (CAP) - EMEA/H/C/004514/MEA 003.10

Applicant: Almirall S.A

PRAC Rapporteur: Adam Przybylkowski

Scope: From Initial MAA:
5th Annual Interim Results for PASS No.: M-14745-40
Title: Tildrakizumab Post-Authorisation Safety Study (PASS) in European Psoriasis Registries.
To collect long-term safety data in particular relating to event of special interest (important potential risks and pregnancy related outcomes) for tildrakizumab. (Malignancies, MACEs, Serious infections, SIBH, Hypersensitivity, IBD, Safety in pregnant and lactating women).
To further characterise the long-term safety profile of tildrakizumab in the treatment of psoriasis under conditions of routine clinical care

Action: For adoption of advice to CHMP

7.6. Others

7.6.1. Buprenorphine - SIXMO (CAP) - EMEA/H/C/004743/ANX 002.1

Applicant: L. Molteni & C. dei Fratelli Alitti Societa di Esercizio S.p.A.

PRAC Rapporteur: Adam Przybylkowski

Scope: From Initial MAA:
First Progress Report for PASS MOLTeNI-2019-01 (EUPAS1000000092)
A prospective, observational (non-interventional), post-authorisation safety cohort study to evaluate the incidence of the breakages and insertion/removal complications of buprenorphine implants (Sixmo) in the routine clinical care

Action: For adoption of advice to CHMP

7.6.2. Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/MEA 011.1

Applicant: Sanofi Winthrop Industrie

PRAC Rapporteur: Kimmo Jaakkola

Scope: From II/0060:
Progress Report for PASS CSA0014 DUPI PEDISTAD
Title: Registry-based study to evaluate the long term safety of dupilumab in children aged ≥ 6 months to <6 years with moderate-to-severe Atopic Dermatitis using the PEDISTAD registry

Action: For adoption of advice to CHMP

7.6.3. Ganaxolone - ZTALMY (CAP) - EMEA/H/C/005825/MEA 014

Applicant: Marinus Pharmaceuticals Emerald Limited

PRAC Rapporteur: Adam Przybylkowski

Scope: From inital MAA
One-Year-Update for CDD-IPR-CDD-01: CDKL5
Non-interventional, observational, international, prospective, natural history registry of up to 500 patients diagnosed with CDD. Deficiency Disorder (CDD) International Patient Registry (IPR)

Action: For adoption of advice to CHMP

7.6.4. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/MEA 033.8

Applicant: Janssen Biologics B.V.

PRAC Rapporteur: Karin Bolin

Scope: From II-0063
5th Annual Progress Report for PASS No. MK-8259-050:
An observational post-approval safety studyof golimumab in treatment of poly-articular Juvenile Idiopathic Arthritis (pJIA) using the German Biologics JIA Registry (BiKeR)

Action: For adoption of advice to CHMP

7.6.5. Ivosidenib - TIBSOVO (CAP) - EMEA/H/C/005936/MEA 003.2

Applicant: Les Laboratoires Servier

PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: ***Feasibility assessment for IMPACTA***
Cross-sectional study to assess the effectiveness of the patients' alert card to inform on the risk of differentiation syndrome in AML patients treated with TIBSOVO (Ivosidenib)

Action: For adoption of advice to CHMP

7.6.6. Plasmodium falciparum and hepatitis b vaccine (recombinant, adjuvanted) - MOSQUIRIX (Art 58[15]) - EMA/PAM/0000242859

Applicant: GlaxoSmithKline Biologicals

[15] Article 58 of Regulation (EC) No 726/2004 allows the Committee for Medicinal Products for Human Use (CHMP) to give opinions, in co-operation with the World Health Organisation (WHO) on medicinal products for human use that are intended exclusively for markets outside of the European Union (EU)

PRAC Rapporteur: Jean-Michel Dogné

Scope: Submission of the 11th progress report for study EPI-MAL-003: a Phase IV prospective observational study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa

Action: For adoption of advice to CHMP

7.6.7. Naldemedine - RIZMOIC (CAP) - EMEA/H/C/004256/MEA 001.8

Applicant: Shionogi B.V.

PRAC Rapporteur: Eamon O'Murchu

Scope: From Initial MAA:
3rd Annual Progress Report for PASS / Product ref. number: S-297995
An Observational Post-Authorisation Safety Study (PASS) of Patients with Chronic Opioid Use for Non-Cancer and Cancer Pain who have Opioid-Induced Constipation (OIC) [period 01 Oct 2017 to 30 Sept 2023]

Action: For adoption of advice to CHMP

7.6.8. Nonacog beta pegol - REFIXIA (CAP) - EMEA/H/C/004178/ANX 001.2

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Gabriele Maurer

Scope: From initial MAA
6th Progress Report (yearly) for PASS NN7999-4031/Paradigm 8
A Non-Interventional Post-Authorisation Safety Study (PASS) in male haemophilia B patients receiving Nonacog Beta Pegol (N9-GP) prophylaxis treatment

Action: For adoption of advice to CHMP

7.6.9. Odevixibat - KAYFANDA (CAP) - EMEA/H/C/006462/SOB 001

Applicant: Ipsen Pharma

PRAC Rapporteur: Adam Przybylkowski

Scope: From initial MAA
Feasibility Assessment for PASS CLIN-60240-034 (imposed/non-interventional)
Prospective Registry-Based Study of the Long-Term Safety of Odevixibat in Patients with Alagille syndrome (ALGS)

Action: For adoption of advice to CHMP

7.6.10. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 012.6

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Petar Mas

Scope: First annual progress report for PASS P21-825
Evaluation of the Effectiveness of Additional Risk Minimisation Measures for Upadacitinib in

the Treatment of Atopic Dermatitis)

Action: For adoption of advice to CHMP

7.6.11. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/MEA 014.4

Applicant: AbbVie Deutschland GmbH & Co. KG

PRAC Rapporteur: Petar Mas

Scope: First Annual Progress Report for PASS P21-824
Title: A study of growth and development in adolescents with atopic dermatitis who receive upadacitinib

Action: For adoption of advice to CHMP

7.6.12. Vosoritide - VOXZOGO (CAP) - EMEA/H/C/005475/MEA 005.5

Applicant: BioMarin International Limited

PRAC Rapporteur: Zane Neikena

Scope: From Initial MAA:
SECOND BI-ANNUAL REPORT for PASS Study 111-603 (26 August 2023-25 August 2024): A multicenter, non-interventional study to evaluate long-term safety in patients with achondroplasia treated with Voxzogo (vosoritide)

Action: For adoption of advice to CHMP

7.7. New Scientific Advice

7.8. Ongoing Scientific Advice

7.9. Final Scientific Advice (Reports and Scientific Advice letters)

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Defibrotide - DEFITELIO (CAP) - EMEA/H/C/002393/S/0069 (without RMP)

Applicant: Gentium S.r.l.

PRAC Rapporteur: Mari Thorn

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.2. Conditional renewals of the marketing authorisation

8.2.1. Entrectinib - ROZLYTREK (CAP) - EMEA/H/C/004936/R/0026 (without RMP)

Applicant: Roche Registration GmbH

PRAC Rapporteur: Bianca Mulder

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.2. Futibatinib - LYTGOBI (CAP) - EMEA/H/C/005627/R/0008 (without RMP)

Applicant: Taiho Pharma Netherlands B.V.

PRAC Rapporteur: Mari Thorn

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.2.3. Glofitamab - COLUMVI (CAP) - EMEA/H/C/005751/R/0012 (without RMP)

Applicant: Roche Registration GmbH

PRAC Rapporteur: Jana Lukacisinova

Scope: Conditional renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3. Renewals of the marketing authorisation

8.3.1. Amikacin - ARIKAYCE LIPOSOMAL (CAP) - EMEA/H/C/005264/R/0014 (with RMP)

Applicant: Insmed Netherlands B.V.

PRAC Rapporteur: Jean-Michel Dogné

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.2. Arsenic trioxide - ARSENIC TRIOXIDE MEDAC (CAP) - EMEA/H/C/005218/R/0006 (without RMP)

Applicant: medac Gesellschaft fur klinische Spezialpraparate mbH

PRAC Rapporteur: Tiphaine Vaillant

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.3. Cabazitaxel - CABAZITAXEL ACCORD (CAP) - EMEA/H/C/005178/R/0012 (without RMP)

Applicant: Accord Healthcare S.L.U.

PRAC Rapporteur: Tiphaine Vaillant

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.4. Filgotinib - JYSELECA (CAP) - EMEA/H/C/005113/R/0038 (without RMP)

Applicant: Alfasigma S.p.A.

PRAC Rapporteur: Petar Mas

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.5. Ivacaftor, tezacaftor, elexacaftor - KAFTRIO (CAP) - EMEA/H/C/005269/R/0059 (without RMP)

Applicant: Vertex Pharmaceuticals (Ireland) Limited

PRAC Rapporteur: Martin Huber

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.6. Melphalan - PHELINUN (CAP) - EMEA/H/C/005173/R/0005 (without RMP)

Applicant: ADIENNE S.r.l.

PRAC Rapporteur: Mari Thorn

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

8.3.7. Methylthioninium chloride - LUMEBLUE (CAP) - EMEA/H/C/002776/R/0007 (without RMP)

Applicant: Cosmo Technologies Limited

PRAC Rapporteur: Mari Thorn

Scope: 5-year renewal of the marketing authorisation

Action: For adoption of advice to CHMP

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. Others

None

10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States' safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC membership

Action: For information

12.1.2. Vote by proxy

Action: For information

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

12.3.1. Scientific Advice Working Party (SAWP) - SAWP-PRAC consultation procedure

Action: For discussion

12.3.2. Patients' and Consumers' Working Party (PCWP) – revised mandate and composition

Action: For adoption

12.3.3. Healthcare Professionals' Working Party (HCPWP) - revised mandate and composition

Action: For adoption

12.3.4. Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) - revised rules of procedure

Action: For adoption

12.4. Cooperation within the EU regulatory network

12.4.1. Health threats and EMA Emergency Task Force (ETF) activities - update

Action: For discussion

12.5. Cooperation with International Regulators

12.5.1. International Conference on Harmonisation (ICH) E22 on general considerations for patient preference studies (PPS)

Action: For discussion

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

None

12.8. Planning and reporting

None

12.9. Pharmacovigilance audits and inspections

12.9.1. Pharmacovigilance systems and their quality systems

None

12.9.2. Pharmacovigilance inspections

None

12.9.3. Pharmacovigilance audits

None

12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

12.10.1. Periodic safety update reports

None

12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Jana Lukacisinova

Action: For discussion

12.10.3. PSURs repository

None

12.10.4. Union reference date list – consultation on the draft list

Action: For adoption

12.11. Signal management

12.11.1. Signal management – feedback from Signal Management Review Technical (SMART) Working Group

None

12.12. Adverse drug reactions reporting and additional reporting

12.12.1. Management and reporting of adverse reactions to medicinal products

None

12.12.2. Additional monitoring

None

12.12.3. List of products under additional monitoring – consultation on the draft list

Action: For adoption

12.13. EudraVigilance database

12.13.1. Activities related to the confirmation of full functionality

None

12.13.2. Eudravigilance annual report 2025

Action: For discussion

12.14. Risk management plans and effectiveness of risk minimisations

12.14.1. Risk management systems

None

12.14.2. Tools, educational materials and effectiveness measurement of risk minimisations

None

12.15. Post-authorisation safety studies (PASS)

12.15.1. Post-authorisation Safety Studies – imposed PASS

None

12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

None

12.21. Others

12.21.1. Draft Reflection Paper on Patient Experience Data (PED) for internal consultation

PRAC lead: Ulla Wändel Liminga, Carla Torre

Action: For discussion

12.21.2. IncreaseNet - Joint Action on Capacity Building - On-the-job training and -coaching pilot plan for National Competent Authorities' assessors

PRAC lead: Martin Huber

Action: For discussion

12.21.3. Revision of Good Pharmacovigilance Practices (GVP) product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases - update

PRAC lead: Jean-Michel Dogné

Action: For discussion

12.21.4. Reflection paper on 'Use of real-world data to generate real-world evidence in non-interventional studies'

Action: For discussion

12.21.5. Revision of EMA policy 0044 on handling of competing interests for scientific committees' members and experts

Action: For discussion

13. Any other business

None

14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: Referral procedures: human medicines | European Medicines Agency (europa.eu)

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/